Etiprednol dicloacetate

Etiprednol dicloacetate (BNP 166) is an anti-inflammatory agent. Etiprednol dicloacetate inhibits eosinophil accumulation. Etiprednol dicloacetate can be used in the research of inflammatory airway diseases, such as asthma[1][2].

Product Specifications

CAS Number

[199331-40-3]

Product Name Alternative

BNP 166; Etiprednol dichloroacetate

UNSPSC

12352211

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/etiprednol-dicloacetate.html

Solubility

10 mM in DMSO

Smiles

ClC(Cl)C(O[C@]1([C@@]2([C@@]([C@@]3([H])[C@]([C@@]4(C(CC3)=CC(C=C4)=O)C)([H])[C@@H](O)C2)([H])CC1)C)C(OCC)=O)=O

Molecular Formula

C24H30Cl2O6

Molecular Weight

485.40

References & Citations

[1]István Kurucz, et al. Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166) . J Pharmacol Exp Ther. 2003 Oct;307 (1) :83-92. |[2]A Miklós, et al. 28-day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period. Pharmazie. 2002 Feb;57 (2) :142-6. |[3]I Kurucz, et al. Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, anti-asthmatic steroid. Pharmazie. 2004 May;59 (5) :412-6.